ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Anti-mycobacterial, cytotoxic effects of Penicillium mallochii ethanol extract, and quantitative detection of its extrolites by lc-q-tof-ms/ms.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Tuberculosis and cancer are the most critical global health problems of our time, and the diseases that cause the most deaths globally. This investigation focused on Penicillium mallochii, a key component of our fungus collection, which is registered in GenBank under the number MG591446. In this study, the minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of P. mallochii ethanol extract (EE) against Mycobacterium species, as well as their cytotoxic activities on cell lines, were investigated. For this purpose, the anti-mycobacterial activity of P. mallochii EE extract was tested against all tuberculosis (TB) strains, including avirulent Mycobacterium tuberculosis H37Ra (MT-H37Ra) and virulent Mycobacterium tuberculosis H37Rv (MT-H37Rv), and six clinical strains (MT-1 to MT-6). It has also been investigated to explore its anticancer activity on HL-60, K562, and A549 cancer cell lines. Additionally, Liquid chromatography-quadrupole time-of-flight tandem mass spectrometry analysis (LC-Q-TOF-MS/MS) enabled the identification of a total of four compounds in the EE, including harmane, kojic acid, simvastatin, and lovastatin. We have provided information about its extrolite content and antituberculosis and cytotoxic effects. P. mallochii is a potential microorganism for future medical drug studies due to its promising antituberculosis activity, cytotoxic effects, and valuable extrolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.